To further confirm the ivosidenib-mediated sensitization of cancer cells to PARPi, the BRCA1/2-WT breast cancer cell line MDA-MB-231, MCF-7, and BRCA1/2 WT ovarian cancer cell A2780, OVCAR-3 cells were treated with increasing concentrations of Olaparib in the presence or absence of 2 μM of ivosidenib. This evidence concerns the gene BRCA1 and ovarian cancer.